Currently, 42 AD immunotherapy clinical trials are underway, which include 2 active immunizations and 15 monoclonal antibodies (mAbs) targeting various forms of Aβ or tau (Table 1, Table 2 and Table 3). This evidence concerns the gene MAPT and Alzheimer disease.